Format

Send to

Choose Destination
Adv Ther. 2019 May;36(5):997-1010. doi: 10.1007/s12325-019-00920-x. Epub 2019 Mar 16.

The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview.

Author information

1
Casimir, Plymouth, MA, USA. mariellec@casimirtrials.com.
2
Hyman, Phelps & McNamara, P.C., Washington, DC, USA.
3
Stealth BioTherapeutics Inc., Newton, MA, USA.
4
Casimir, Plymouth, MA, USA.

Abstract

INTRODUCTION:

The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and relatively few validated, disease-specific outcome measures. Incorporating qualitative research into rare disease clinical trials may help sponsors, regulators, payers, and prescribers to better understand the real-world and patient-specific impact of a potential therapy. This paper provides a methodologic overview of the use of Patient and Caregiver Perception of Change (PPC and CPC) Assessments utilizing patient and caregiver video interviews to complement the data captured by traditional endpoints in rare disease clinical trials.

METHODS:

Incorporating qualitative patient and caregiver video interviews into clinical trials allows for the rigorous capture of patient experiences and caregiver observations. Interview guides informed by input from key stakeholders provide the opportunity to solicit structured feedback on experiences before, during, and after the clinical trial. Patients and caregivers can complete their video interviews in a study mobile application, and interview transcripts are analyzed by independent coders. Themes are summarized by the treatment group and individual patient, which adds context to the clinical outcome measures of how patients feel and function, as well as elucidates the degree of change that is meaningful to patients and caregivers. The qualitative results can be compared to the data captured in clinical trials to assess data concordance.

CONCLUSION:

Capturing patient experience data with sufficient rigor allows it to contribute to the body of evidence utilized in regulatory, payer, and prescriber decision-making. Adding PPC and CPC Assessments to rare disease clinical trials offers an innovative and powerful way to tap into the unique insights of patients and their families to develop a fuller picture of the patient experience in the clinical trial.

FUNDING:

Stealth BioTherapeutics Inc.

KEYWORDS:

Clinical outcome assessment; Genetic disease; Mixed methods research; Observer-reported outcomes; Patient experience data; Patient focused drug development; Patient-reported outcomes; Qualitative research; Rare diseases

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center